2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.78 (Poster) First-line nivolumab + ipilimumab + chemotherapy in metastatic non-small cell lung cancer: CheckMate 9LA 4-year clinical update

PP01.78 (Poster) First-line nivolumab + ipilimumab + chemotherapy in metastatic non-small cell lung cancer: CheckMate 9LA 4-year clinical update

Back to course

Pdf Summary

The document discusses the findings of a study that investigated the effectiveness and safety of a first-line treatment option for advanced non-small cell lung cancer (NSCLC) using a combination of nivolumab, ipilimumab, and chemotherapy. The study found that patients treated with this combination therapy had improved overall survival rates compared to those treated with chemotherapy alone. The benefits were observed regardless of tumor PD-L1 expression or histology, with greater improvements seen in patients with PD-L1 expression of 1% or squamous NSCLC. Discontinuation of the treatment due to adverse events did not negatively impact the long-term clinical or efficacy benefits. No new safety concerns were identified. The results support the use of this combination therapy as a first-line option for patients with metastatic NSCLC, particularly those with PD-L1 expression of 1% or squamous histology. The authors acknowledge the contributions of patients, study teams, and collaborators. The study was presented at a conference on lung cancer. Overall, the study demonstrates that this treatment regimen is an effective option for managing advanced NSCLC.

Asset Subtitle

Firas Badin

Keywords

non-small cell lung cancer

NSCLC

nivolumab

ipilimumab

chemotherapy

combination therapy

overall survival rates

tumor PD-L1 expression

squamous NSCLC

metastatic NSCLC